Grafa
Imricor Medical Systems gains FDA clearance for Vision-MR diagnostic catheter
Image for illustrative purposes only. Not a real photo.

Imricor Medical Systems gains FDA clearance for Vision-MR diagnostic catheter

Share

Imricor Medical Systems (ASX:IMR) announced that the US Food and Drug Administration has granted 510(k) clearance for its Vision-MR Diagnostic Catheter, marking the company’s first FDA-approved device.

The catheter, designed for use under real-time magnetic resonance imaging guidance, is a key component of Imricor's MRI-compatible electrophysiology platform.

FDA clearance allows the company to commercially market the device in the United States, the world’s largest EP market. Imricor anticipates additional regulatory approvals this year as it rolls out its full MRI-guided EP platform.

Steve Wedan, Chair and CEO of Imricor, described the milestone as "an extraordinarily big deal" for the company and praised the team’s efforts in bringing the first US device to market.

At the time of reporting, Imricor Medical Systems' share price was $1.85.

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.